TRDA News and Press, Entrada Therapeutics Inc. From 03/30/22

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Entrada Therapeutics press release (NASDAQ:TRDA): Q4 GAAP EPS of -$0.89 misses by $0.17. As of December 31, 2021, cash and cash equivalents were $291.1M For further details see: Entrada Therapeutics GAAP EPS of -$0.89 misses by $0.17

On track to submit IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in 2H 2022 $291.1 million in cash and cash equivalents as of December 31, 2021 to advance pipeline of EEV-therapeutic candidates BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Entrada Ther...

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipa...

BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that the ...

Entrada Therapeutics (NASDAQ:TRDA): Q3 GAAP EPS of -$9.78 may not be comparable wit consensus of -$0.83M As of September 30, 2021, cash and cash equivalents were $122.2M.  Press Release For further details see: Entrada Therapeutics EPS misses by $8.95

Successful completion of upsized $208.7 million Initial Public Offering BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle...

Evercore ISI analyst Jonathan Miller initiates Entrada Therapeutics (NASDAQ:TRDA) +16% coverage with an outperform rating and no price target. Miller believes that EEV platform is a best-in-class delivery technology seeing preclinical results that "far exceed first-gen constructs" f...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEV™) therapeutic...